How it works:
Cagrilintide is an amylin analogue (amyloid mimetic) that binds to amylin receptors in the brain and gastrointestinal tract. It reduces appetite, delays gastric emptying, promotes weight loss, and improves glycaemic control in patients with type 2 diabetes.
Recommended for:
Studies and research:
Cagrilintide is used in research studies to evaluate its efficacy in obesity and type 2 diabetes therapy. Its main effects are appetite suppression, body weight control, and improved glycaemic regulation.
Cagrilintide is supplied as a lyophilised powder to be reconstituted with a sterile solvent before injection. The dosage and regimen depend on the specific research protocol and clinical study design.
Side effects: